A phase 2 trial of HQK-1001 in HbE-β thalassemia demonstrates HbF induction and reduced anemia.
作者信息
Patthamalai Poramin, Fuchareon Suthat, Chaneiam Nattawara, Ghalie Richard G, Chui David H K, Boosalis Michael S, Perrine Susan P
机构信息
Mahidol University, Bangkok, Thailand.
出版信息
Blood. 2014 Mar 20;123(12):1956-7. doi: 10.1182/blood-2013-11-538470.
Abstract
摘要
相似文献
1
A phase 2 trial of HQK-1001 in HbE-β thalassemia demonstrates HbF induction and reduced anemia.
Blood. 2014 Mar 20;123(12):1956-7. doi: 10.1182/blood-2013-11-538470.
2
A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in β-thalassaemia intermedia.
Br J Haematol. 2014 Feb;164(3):456-8. doi: 10.1111/bjh.12635. Epub 2013 Nov 13.
3
A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia.
Br J Haematol. 2013 May;161(4):587-93. doi: 10.1111/bjh.12304. Epub 2013 Mar 27.
4
HbF in HbE/β-thalassemia: A clinical and laboratory correlation.
Hematology. 2015 Jul;20(6):349-53. doi: 10.1179/1607845414Y.0000000203. Epub 2014 Sep 22.
5
A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.
Am J Hematol. 2013 Nov;88(11):E255-60. doi: 10.1002/ajh.23533. Epub 2013 Oct 3.
6
Reversing ontogeny.
N Engl J Med. 1993 Jan 14;328(2):129-31. doi: 10.1056/NEJM199301143280210.
7
The emerging role of fetal hemoglobin induction in non-transfusion-dependent thalassemia.
Blood Rev. 2012 Apr;26 Suppl 1:S35-9. doi: 10.1016/S0268-960X(12)70011-5.
8
A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease.
Am J Hematol. 2012 Nov;87(11):1017-21. doi: 10.1002/ajh.23306. Epub 2012 Aug 7.
9
A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders.
N Engl J Med. 1993 Jan 14;328(2):81-6. doi: 10.1056/NEJM199301143280202.
10
Induction of fetal globin in beta-thalassemia: Cellular obstacles and molecular progress.
Ann N Y Acad Sci. 2005;1054:257-65. doi: 10.1196/annals.1345.033.
引用本文的文献
1
Genetic Modifiers of Hemoglobin Expression from a Clinical Perspective in Hemoglobinopathy Patients with Beta Thalassemia and Sickle Cell Disease.
Int J Mol Sci. 2024 Nov 5;25(22):11886. doi: 10.3390/ijms252211886.
2
Combinatorial targeting of epigenome-modifying enzymes with decitabine and RN-1 synergistically increases HbF.
Blood Adv. 2023 Aug 8;7(15):3891-3902. doi: 10.1182/bloodadvances.2022009558.
3
Foetal haemoglobin inducers for reducing blood transfusion in non-transfusion-dependent beta-thalassaemias.
Cochrane Database Syst Rev. 2023 Jan 13;1(1):CD013767. doi: 10.1002/14651858.CD013767.pub2.
4
Trienone analogs of curcuminoids induce fetal hemoglobin synthesis via demethylation at γ-globin gene promoter.
Sci Rep. 2021 Apr 20;11(1):8552. doi: 10.1038/s41598-021-87738-2.
5
Targeting sickle cell disease root-cause pathophysiology with small molecules.
Haematologica. 2019 Sep;104(9):1720-1730. doi: 10.3324/haematol.2018.207530. Epub 2019 Aug 8.
6
Fetal Hemoglobin Induction by Epigenetic Drugs.
Semin Hematol. 2018 Apr;55(2):60-67. doi: 10.1053/j.seminhematol.2018.04.008. Epub 2018 Apr 22.
7
Evolution of hemoglobin loci and their regulatory elements.
Blood Cells Mol Dis. 2018 May;70:2-12. doi: 10.1016/j.bcmd.2017.08.001. Epub 2017 Aug 9.
8
Novel Inducers of Fetal Globin Identified through High Throughput Screening (HTS) Are Active In Vivo in Anemic Baboons and Transgenic Mice.
PLoS One. 2015 Dec 29;10(12):e0144660. doi: 10.1371/journal.pone.0144660. eCollection 2015.
9
Genomic approaches to identifying targets for treating β hemoglobinopathies.
BMC Med Genomics. 2015 Jul 29;8:44. doi: 10.1186/s12920-015-0120-2.
10
Pharmacological Induction of Human Fetal Globin Gene in Hydroxyurea-Resistant Primary Adult Erythroid Cells.
Mol Cell Biol. 2015 Jul;35(14):2541-53. doi: 10.1128/MCB.00035-15. Epub 2015 May 18.
本文引用的文献
1
A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia.
Br J Haematol. 2013 May;161(4):587-93. doi: 10.1111/bjh.12304. Epub 2013 Mar 27.
2
Fetal globin gene inducers: novel agents and new potential.
Ann N Y Acad Sci. 2010 Aug;1202:158-64. doi: 10.1111/j.1749-6632.2010.05593.x.
3
The inherited diseases of hemoglobin are an emerging global health burden.
Blood. 2010 Jun 3;115(22):4331-6. doi: 10.1182/blood-2010-01-251348. Epub 2010 Mar 16.
4
A genome-wide association identified the common genetic variants influence disease severity in beta0-thalassemia/hemoglobin E.
Hum Genet. 2010 Mar;127(3):303-14. doi: 10.1007/s00439-009-0770-2.
5
Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study.
Blood. 2010 Mar 11;115(10):1886-92. doi: 10.1182/blood-2009-09-243154. Epub 2009 Dec 23.
6
Control of fetal hemoglobin: new insights emerging from genomics and clinical implications.
Hum Mol Genet. 2009 Oct 15;18(R2):R216-23. doi: 10.1093/hmg/ddp401.
7
BCL11A is a major HbF quantitative trait locus in three different populations with beta-hemoglobinopathies.
Blood Cells Mol Dis. 2008 Nov-Dec;41(3):255-258. doi: 10.1016/j.bcmd.2008.06.007. Epub 2008 Aug 8.
8
Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia.
Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1620-5. doi: 10.1073/pnas.0711566105. Epub 2008 Feb 1.
9
Changing patterns of thalassemia worldwide.
Ann N Y Acad Sci. 2005;1054:18-24. doi: 10.1196/annals.1345.003.
10
Enhancement of growth and survival and alterations in Bcl-family proteins in beta-thalassemic erythroid progenitors by novel short-chain fatty acid derivatives.
Blood Cells Mol Dis. 2005 Sep-Oct;35(2):217-26. doi: 10.1016/j.bcmd.2005.06.007.
Zotero 插件